Vistagen Therapeutics (VTGN) Operating Leases (2019 - 2026)
Vistagen Therapeutics (VTGN) posted Operating Leases of $249000.0 for Q1 2026, down 42.23% sequentially from $431000.0 in Q4 2025, and down 73.73% YoY from $948000.0 in Q1 2025.
Vistagen Therapeutics (VTGN) Operating Leases (2019 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Operating Leases for 8 years, with the latest figure at $249000.0 in Q1 2026.
- Quarterly Operating Leases fell 73.73% year-over-year to $249000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $249000.0 (down 73.73% YoY) and the FY2026 annual result came in at $249000.0, down 73.73% from the prior year.
- Operating Leases slipped to $249000.0 in Q1 2026 per VTGN's latest filing, from $431000.0 in the prior quarter.
- Over five years, Operating Leases peaked at $2.6 million in Q1 2022 and troughed at $249000.0 in Q1 2026.
- A 5-year average of $1.5 million and a median of $1.6 million in 2024 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2026: Operating Leases fell 17.31% in 2022, then sank 73.73% in 2026.
- Over 5 years, Operating Leases stood at $2.2 million in 2022, then retreated by 23.74% to $1.7 million in 2023, then plunged by 35.21% to $1.1 million in 2024, then tumbled by 61.17% to $431000.0 in 2025, then tumbled by 42.23% to $249000.0 in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $249000.0, $431000.0, and $610000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 249,000.00 |
| Dec 31, 2025 | 431,000.00 |
| Sep 30, 2025 | 610,000.00 |
| Jun 30, 2025 | 783,000.00 |
| Mar 31, 2025 | 948,000.00 |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 1.27 Mn |
| Jun 30, 2024 | 1.42 Mn |
| Mar 31, 2024 | 1.57 Mn |
| Dec 31, 2023 | 1.71 Mn |
| Sep 30, 2023 | 1.85 Mn |
| Jun 30, 2023 | 1.99 Mn |
| Mar 31, 2023 | 2.12 Mn |
| Dec 31, 2022 | 2.25 Mn |
| Sep 30, 2022 | 2.37 Mn |
| Jun 30, 2022 | 2.49 Mn |
| Mar 31, 2022 | 2.61 Mn |
| Dec 31, 2021 | 2.72 Mn |
| Sep 30, 2021 | 3.14 Mn |
| Jun 30, 2021 | 3.25 Mn |